Results 21 to 30 of about 2,249,117 (300)

Expert Panel Consensus for Addressing Anti-VEGF Treatment Challenges of Diabetic Macular Edema in Spain [PDF]

, 2022
PURPOSE: The treatment of diabetic macular edema (DME) has evolved rapidly in the past decade, highlighting the need to address the challenges of routine clinical practice decision-making through expert consensus agreements.
Flores-Moreno, Ignacio, Moreno, Luis, Arrevola-Velasco, Luis, Beckford, Carlos, Cobo-Soriano, Rosario, Contreras, Inés, Fernández-Vigo, José Ignacio, Pareja, Jesús, Crespo, María José, Cobo Soriano, Rosario, Ignacio Fernandez-Vigo, Jose, Martín, María Dolores   +11 more
core   +1 more source

Anti VEGF for post op CME- Boon or Bane!

TNOA Journal of Ophthalmic Science and Research, 2022
Cataract surgery has advanced in techniques and instrumentation over the years, but complications such as cystoid macular edema (CME) do occur even after uneventful surgery.
Roshni Mohan, M Arthi, S Balamurugan
doaj   +1 more source

Factors Involved in Anti-VEGF Treatment Decisions for Neovascular Age-Related Macular Degeneration: Insights from Real-World Clinical Practice [PDF]

Clinical Ophthalmology
Glenn Yiu,1 Shilpa Gulati,2 Victoria Higgins,3 Emily Coak,3 Daniel Mascia,3 Eunice Kim,4 Galin Spicer,4 David Tabano4 1Department of Ophthalmology & Vision Science, University of California, Davis Health, Sacramento, CA, USA; 2New England Retina ...
Yiu G, Gulati S, Higgins V, Coak E, Mascia D, Kim E, Spicer G, Tabano D   +7 more
doaj   +1 more source

Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo

Scientific Reports, 2021
The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) axis is an essential regulator of angiogenesis and important therapeutic target in cancer.
Tetsuo Mashima, Takeru Wakatsuki, Naomi Kawata, Myung-Kyu Jang, Akiko Nagamori, Haruka Yoshida, Kenichi Nakamura, Toshiro Migita, Hiroyuki Seimiya, Kensei Yamaguchi   +9 more
doaj   +1 more source

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study

Frontiers in Oncology, 2021
BackgroundIn recent years, immune checkpoint inhibitors (ICIs) in combination with chemotherapy have increased survival in patients with advanced non-small cell lung cancer (NSCLC).
Keiko Tanimura, Tadaaki Yamada, Ayaka Omura, Shinsuke Shiotsu, Nobutaka Kataoka, Takayuki Takeda, Ryusuke Taniguchi, Takahiro Yamada, Mayumi Takeuchi, Yusuke Chihara, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama   +14 more
doaj   +1 more source

Immunoreactivity of the anti-VEGF-A121 and anti-VEGF-A165 monoclonal antibodies.

, 2023
Mixture of rhVEGF-A121, rhVEGF-A165 and rhVEGF-A189 (50 μg each) were subjected to 15% SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE). The transferred membrane was detected with anti-VEGF-A polyclonal antibody (left panel), anti-VEGF-A165 monoclonal ...
Yoko Oyama (600027), Aryal Bibek (15198524), Taiji Sakamoto (104961), Kazunori Takenouchi (15198521), Kazuhiko Higurashi (15198527), Shingo Yamada (339487), Hideaki Kanda (15198539), Akito Tabaru (15198530), Sadayuki Higashi (15198533), Hiroto Terasaki (104937), Chieko Fujisaki (15198536), Keiichi Inoue (466261), Masashi Okawa (8951294), Kiyonori Tanoue (14928179), Yoshiharu Soga (13883911), Munekazu Yamakuchi (220194), Teruto Hashiguchi (464609)   +16 more
core   +1 more source

Anti-VEGF Therapies in the Clinic [PDF]

Cold Spring Harbor Perspectives in Medicine, 2012
The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of anticancer regimens for many tumor types. This review is intended to highlight some of the most important clinical successes and failures of anti-VEGF therapies, and where possible, to suggest ...
Kellen L, Meadows, Herbert I, Hurwitz
openaire   +2 more sources

Cost-effectiveness of the anti-vascular endothelial growth factor intravitreal injection and panretinal photocoagulation for patients with proliferative diabetic retinopathy in South Korea

BMC Health Services Research, 2023
Background We determined the cost-effectiveness of the anti-vascular endothelial growth factor (VEGF) intravitreal injection versus panretinal photocoagulation (PRP) for patients with proliferative diabetic retinopathy (PDR) in South Korea.
Hyeon-Jeong Lee, Songhee Cho, Jungeun Park, Yan Jin, Hyung Min Kim, Donghyun Jee   +5 more
doaj   +1 more source

Refractive status and ocular characteristics of preschool children with retinopathy of prematurity after different treatments [PDF]

International Journal of Ophthalmology
AIM: To compare the changes in preschool refractive status, ocular biological parameters, and higher-order aberrations in children with retinopathy of prematurity (ROP) after retinal laser photocoagulation or anti-vascular endothelial growth factor (anti-
Wu-Yang Jiang, Man-Hong Li, Hao Wang, Dong Niu, Yu-Sheng Wang, Zi-Feng Zhang   +5 more
doaj   +1 more source

Comparison of micropulse subthreshold laser plus anti-VEGF versus anti-VEGF alone in diabetic macular edema: Systematic review

Indian Journal of Ophthalmology, 2023
Intravitreal injection of anti- Vascular Endothelial Growth Factor (VEGF)is commonly used to treat patients with diabetic macular edema (DME). However, the injection alone requires high cost and compliance.
Parangeni M Lubis, Marcelius P Prabaniswara, Andi Arus Victor   +2 more
doaj   +1 more source